|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
CD117-Ckit, IHC with Interpretation [11230X]
Test Code112308
CPT Codes
88342
Preferred Specimen
Formalin-fixed, paraffin-embedded tissue block
Other Acceptable Specimens
Minimum: 3 unstained, positively charged slides
Instructions
Please include surgical pathology report.
Transport Container
IHC Specimen Transport Kit
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Indefinitely
Refrigerated: Indefinitely
Frozen: Unacceptable
Refrigerated: Indefinitely
Frozen: Unacceptable
Methodology
Immunohistochemistry (IHC)
Setup Schedule
Set up: Mon-Fri; Report available: 2 days
Reference Range
Interpretive report
Clinical Significance
Testing for CD117/c-kit expression may be a useful tool for the identification of several malignant neoplasma expressing c-kit, including gastrointestinal stromal tumors (GISTS), mast cell diseases, acute myeloid leukemia (AML), small cell lung carcinoma (SCLC), and Ewing's sarcoma. It may also aid in differentiating gastrointestinal stromal tumors (GISTS) from other intra-abdominal mesenchymal tumors.
Recent studies have indicated that the tyrosine kinase inhibitor, STI571 (Gleeva), may be effective in treating CD117/c-kit positive tumors. Therefore, testing tumors for CD117/c-kit immunoreactivity can assist in both diagnosis and the prediction of drug sensitivity to tyrosine kinase inhibitor STI571 treatment.
Recent studies have indicated that the tyrosine kinase inhibitor, STI571 (Gleeva), may be effective in treating CD117/c-kit positive tumors. Therefore, testing tumors for CD117/c-kit immunoreactivity can assist in both diagnosis and the prediction of drug sensitivity to tyrosine kinase inhibitor STI571 treatment.